Marker Therapeutics, Inc. (NASDAQ:MRKR) Short Interest Up 43.5% in December

Marker Therapeutics, Inc. (NASDAQ:MRKR) was the target of a significant increase in short interest during the month of December. As of December 15th, there was short interest totaling 335,196 shares, an increase of 43.5% from the November 30th total of 233,661 shares. Based on an average daily trading volume, of 311,655 shares, the short-interest ratio is currently 1.1 days. Currently, 2.2% of the shares of the company are short sold. Currently, 2.2% of the shares of the company are short sold. Based on an average daily trading volume, of 311,655 shares, the short-interest ratio is currently 1.1 days.

Hedge Funds Weigh In On Marker Therapeutics

Several hedge funds have recently modified their holdings of the stock. Virtu Financial LLC bought a new position in shares of Marker Therapeutics during the third quarter worth $25,000. Two Sigma Investments LP purchased a new stake in Marker Therapeutics in the 3rd quarter worth $33,000. Finally, Jane Street Group LLC bought a new position in shares of Marker Therapeutics during the 2nd quarter valued at about $33,000. Hedge funds and other institutional investors own 22.39% of the company’s stock.

Marker Therapeutics Stock Performance

Shares of Marker Therapeutics stock traded up $0.09 during trading hours on Monday, hitting $1.52. The company’s stock had a trading volume of 429,021 shares, compared to its average volume of 642,898. The company has a market cap of $25.34 million, a PE ratio of -1.24 and a beta of 1.35. The business has a 50 day moving average price of $1.15 and a two-hundred day moving average price of $1.21. Marker Therapeutics has a 12-month low of $0.81 and a 12-month high of $4.07.

Marker Therapeutics (NASDAQ:MRKR) last released its earnings results on Thursday, November 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.57. The firm had revenue of $1.23 million during the quarter, compared to analysts’ expectations of $0.72 million. Marker Therapeutics had a negative return on equity of 92.35% and a negative net margin of 304.56%. As a group, research analysts anticipate that Marker Therapeutics will post -0.65 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on MRKR shares. Zacks Research raised shares of Marker Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, November 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Marker Therapeutics in a report on Monday, December 22nd. HC Wainwright assumed coverage on Marker Therapeutics in a research note on Monday, December 8th. They issued a “buy” rating and a $10.00 price objective on the stock. UBS Group reaffirmed a “buy” rating on shares of Marker Therapeutics in a research report on Monday, December 8th. Finally, Wall Street Zen lowered shares of Marker Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, November 30th. Three investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Marker Therapeutics has a consensus rating of “Buy” and an average target price of $10.17.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.